Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene

EU orphan designation number: EU/3/12/998   
Active ingredient: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene
Indication: Treatment of Wiskott-Aldrich syndrome
Sponsor: Orchard Therapeutics (Europe) Limited
108 Cannon Street, London EC4N 6EU, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
8/06/2012 Orphan designation EMA/OD/014/12 (2012)3842 of 6/06/2012
11/10/2013 Change of name and/or address of sponsor
9/12/2014 Transfer of orphan designation EMA/OD/014/12/T/01 (2014)9542 of 5/12/2014
27/07/2018 Transfer of orphan designation EMA/OD/014/12/T/02 (2018)5062 of 25/07/2018
11/03/2019 Change of name and/or address of sponsor